Wegovy price per month in the UK: the full picture

Step 1: understand what the quoted price should include

Private Wegovy pricing in the UK is quoted per four-week pen, and the dose you are prescribed directly affects the monthly cost. Treatment starts at 0.25 mg and moves through a titration schedule set by your prescriber, with 2.4 mg as the standard long-term maintenance dose and 7.2 mg now available as the maximum, approved by the MHRA in April 2026. Lower doses cost less per pen; maintenance doses more. That is normal and expected.

What is not always clear from a quoted price is whether it already covers the consultation, the prescription, and delivery. Some providers charge each of these separately. You may see a figure that looks reasonable, add a consultation fee and a prescription fee, and find the real monthly outlay is noticeably higher. The NHS England overview of weight-management injections is a useful independent reference point for understanding what a full pathway should involve.

A legitimate price for a prescription medicine should also reflect a genuine clinical process: identity verification, a review of your health history, and a prescriber who actually reads your answers rather than a system that processes them automatically. That infrastructure costs something. When a price seems unusually low, it is worth asking what has been left out.

Step 2: know where Eli Lilly's 2025 price rise sits in the picture

Pricing shifted meaningfully in late 2025. Eli Lilly raised Mounjaro's UK list price from 1 September 2025 (the top-dose list price moved from around £122 to around £330 per four-week pen) and Novo Nordisk's private Wegovy pricing has followed a comparable trajectory across the market. Private providers typically price above list to cover dispensing, clinical review and fulfilment costs. Reported private prices since then range roughly £149–£375 per month depending on the dose and the service, though individual providers vary and figures shift. If you are researching how much Wegovy costs per month, treat any single figure you read as a snapshot, not a guarantee, and our breakdown of Wegovy costs per month sets out how those figures are typically structured across doses.

It is also worth noting that Wegovy is a semaglutide injection regulated under strict prescription rules. The MHRA has warned publicly about counterfeit weight-loss pens sold online (some containing insulin rather than semaglutide) and advises verifying any online pharmacy on the GPhC register before purchasing. A price that sits well below the market range is one of the clearest red flags.

Step 3: what nume's position is, and why

We are not the cheapest option and we do not intend to be. Keeping prices as low as possible would mean cutting something, and the things most easily cut (thorough clinical review, responsive aftercare, supply-chain rigour) are the things that matter most when you are taking a prescription medicine long term.

At nume, one transparent monthly price covers everything listed above: consultation, prescription, treatment, and next-working-day DPD delivery. There are no add-on fees, no subscription that continues automatically, and no renewal that skips clinical review. Before every repeat, a GPhC-registered Independent Prescriber looks at your case again. You can check what that process looks like on our about us page, and verify our pharmacy on the GPhC register at registration number 9012878.

Current treatment pricing is shown on the weight-loss treatments page, we do not print per-pen prices in body copy because doses vary and the right dose for you is a clinical decision, not a product choice. If you want an honest sense of the monthly cost of Wegovy in the UK compared with what different services include, that detail sits there, and if you are wondering whether NHS funding could apply to your situation, our guide to Wegovy cost per month on the NHS in the UK explains the current access criteria and how private costs compare.

Step 4: why 'cheapest' is the wrong measure for a prescription medicine

It is completely understandable to look for value, treatment that may run for months or years is a real financial commitment, and the frustration of comparing prices across a fragmented market is something our prescribers hear about regularly. But for a prescription-only medicine, the cheapest listing answers the wrong question.

The right questions are: Is this pharmacy registered with the GPhC? Will a qualified human prescriber review my consultation? Is the medicine coming from the licensed UK supply chain? The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk allows you to report suspect sellers, and the regulator has been explicit that sellers offering these medicines without a full clinical assessment are operating outside the law. NICE's appraisal of semaglutide for weight management, TA875, sets out what appropriate clinical oversight should look like.

The results people see on Wegovy depend heavily on consistent, properly supervised treatment. A service that skips clinical infrastructure to compete on price undermines the very outcomes you are paying for. That is the case for thinking about value rather than cost alone, and it is why we structured our service the way we have. Check your eligibility with our prescribers and see what a properly supported pathway looks like.